Rengalin
ApprovedSmall molecule
Rengalin is one of 28 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Rengalin
MMateria Medica Holding
Approved
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Coumadin
AAbbott
Preclinical
Narcan
SScienture
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rengalin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMateria Medica Holding